Skip to main content
Fig. 3 | BMC Surgery

Fig. 3

From: Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3/4 PVTT following combination therapy of TKIs and PD-1 inhibitors

Fig. 3

Survival analysis of Vp3/4 PVTT patients who received salvage surgery following combination therapy of TKIs and PD-1 inhibitors. A Overall survival and Recurrence-free survival of all cohort: the mOS had not reached, and the mRFS was 11 months (95% CI, 2.68–19.32). B the 3-year portal vein patency rates of all patients were 95.0%. C Overall survival stratified by the Vp classification (P = 0.457). D Recurrence-free survival stratified by the Vp classification (P = 0.985). E Overall survival stratified by overall pCR (P = 0.053). F Recurrence-free survival stratified by overall pCR (P = 0.011). Abbreviations: PVTT portal vein tumor thrombosis, Vp portal vein invasion, mOS median overall survival, mPFS median progression-free survival; pCR pathological complete response

Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us